http://jcps.bjmu.edu.cn

Journal of Chinese Pharmaceutical Sciences ›› 2022, Vol. 31 ›› Issue (6): 471-477.DOI: 10.5246/jcps.2022.06.041

• Drug administration and clinical pharmacy column • Previous Articles     Next Articles

Research progress of sacubitril/valsartan in heart failure patients with preserved ejection fraction

Jingjing Cao, Shujuan Zhao, Chenglong Zhao, Peizhi Ma*()   

  1. Department of Pharmacy, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450003, China
  • Received:2022-02-16 Revised:2022-03-05 Accepted:2022-03-17 Online:2022-06-30 Published:2022-06-30
  • Contact: Peizhi Ma

Abstract:

With the launch of sacubitril/valsartan (ARNI), there are new options for the treatment of heart failure (HF). However, ARNI is currently only used in HF patients with reduced ejection fraction (HFrEF). No evidence shows that no modern treatment can reduce mortality in HF patients with preserved ejection fraction (HFpEF). Therefore, it is urgently necessary clarify whether ARNI can be used in the treatment of HFpEF. In the present study, we summarized the research progress of ARNI in the treatment of HFpEF.

Key words: Preserved ejection fraction, Reduced ejection fraction, Sacubitril/valsartan

Supporting: